- Home
- TIVC vs VIVS Comparison
TIVC vs VIVS Comparison
Compare TIVC & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TIVC | VIVS |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TIVC | VIVS |
|---|---|---|
| Price | $1.40 | $1.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 222.5K | 27.2K |
| Earning Date | 05-14-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $780,000.00 | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.75 | $1.22 |
| 52 Week High | $5.60 | $5.30 |
Technical Indicators
Market Signals| Indicator | TIVC | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 69.31 | 47.62 |
| Support Level | $0.79 | $1.24 |
| Resistance Level | $2.70 | $1.38 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 100.00 | 77.42 |
Price Performance
Historical ComparisonAbout TIVC Tivic Health Systems Inc.
Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.